Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Terran Orbital Corporation of Class Action Lawsuit and Upcoming Deadlines – LLAP

Pomerantz LLP announces that a class action lawsuit has been filed against Terran Orbital Corporation (“Terran” or the “Company”) (NYSE: LLAP) and certain officers.   The class action, filed in the United States District Court for the Southern District Of Florida, and docketed under 24-cv-81191 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Terran securities between August 15, 2023 and August 14, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

 

If you are a shareholder who purchased or otherwise acquired Terran securities during the Class Period, you have until November 26, 2024 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

 

[Click here for information about joining the class action]

 

Terran manufactures and sells satellites for aerospace and defense industries in the United States (“U.S.”) and internationally.  Historically, Lockheed Martin Corporation (“Lockheed”) has been one of Terran’s most significant stakeholders and customers.  As of October 31, 2022, Lockheed owned approximately 9.5% of Terran’s stock, and by May 2, 2024, Lockheed owned an approximate 28.3% stake in the Company.  Likewise, as of December 21, 2021, contracts with Lockheed represented approximately 50% of Terran’s consolidated revenues, whereas Lockheed comprised approximately 70% of Terran’s consolidated revenues during the three months ended June 30, 2024.

 

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) it would take much longer than Defendants had represented to investors and analysts for Terran to convert its contracts with its customers (collectively, “Customer Contracts”) into revenue and free cash flow; (ii) Terran did not have adequate liquidity to operate its business while waiting for the Customer Contracts to generate revenue and free cash flow; (iii) Terran had concealed the true scope and severity of its dire financial situation; and (iv) as a result of the foregoing, Terran’s public statements were materially false and misleading at all relevant times.

 

In February 2023, Terran issued a press release announcing that its wholly owned subsidiary Tyvak Nano-Satellite Systems, Inc. had been awarded a $2.4 billion contract from Rivada Space Networks GmbH (“Rivada”) to produce a total of 300 satellites for Rivada (the “Rivada Contract”).  Throughout the Class Period, Defendants repeatedly represented to investors and analysts that Terran would rapidly convert the Rivada Contract and other Customer Contracts into revenue and free cash flow, and that Terran had ample liquidity to operate its business while waiting to generate revenue and free cash flow from the Customer Contracts.

 

On March 1, 2024, Lockheed made a non-binding offer to acquire all of Terran’s outstanding common stock for $1.00 per share in cash (the “Initial Buyout Offer”).

 

On May 2, 2024, Lockheed disclosed in a filing with the U.S. Securities and Exchange Commission (“SEC”) that, “[o]n April 30, 2024, [it] notified [Terran] that it was withdrawing the [Initial Buyout Offer].”

 

On this news, Terran’s stock price fell $0.22 per share, or 17.05%, to close at $1.07 per share on May 3, 2024.

 

On August 12, 2024, Terran filed its quarterly report for the second quarter of 2024 with the SEC, revealing, inter alia, that the Company had only $14.6 million in cash and debt of approximately $300 million as of June 30, 2024, as well as that it had removed the Rivada Contract from its backlog, thereby reducing the Company’s total backlog by over 88% from $2.7 billion to a mere $312.7 million as of June 30, 2024.

 

On this news, Terran’s stock price fell $0.06 per share, or 8.45%, to close at $0.65 per share on August 12, 2024.

 

Then, on August 15, 2024, Terran and Lockheed issued a joint press release announcing that they had entered into a definitive agreement whereby Lockheed would acquire Terran for $0.25 per share in cash (“Transaction”).  The sale price was well below the (i) $0.40 per share price at which the Company’s stock had closed the day prior, and (ii) the $1.00 per share price that Lockheed had offered in its Initial Buyout Offer.

 

On this news, Terran’s stock price fell $0.157 per share, or 39.25%, to close at $0.243 per share on August 15, 2024.

 

On September 9, 2024, Terran filed a preliminary proxy (“Proxy”) with the SEC in connection with the Transaction. The Proxy revealed that the reason Lockheed had withdrawn the Initial Buyout Offer, and was only willing to offer $0.25 per share in cash to acquire Terran, was because Terran had long suffered from severe liquidity challenges and was on the verge of bankruptcy. The Transaction announced on August 15, 2024, thus represented a materialization of the risks posed by Terran’s severe liquidity challenges that Defendants had deliberately concealed from Terran stockholders throughout the Class Period.

 

As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s securities, Plaintiff and other Class members have suffered significant losses and damages.

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines – ELAN

Pomerantz LLP announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) and certain officers.   The class action, filed in the United States District Court for the District Of Maryland, and docketed under 24-cv-02912  is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

 

If you are a shareholder who purchased or otherwise acquired Elanco securities during the Class Period, you have until December 6, 2024 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

 

[Click here for information about joining the class action]

 

Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals.  The Company is developing, inter alia, Zenrelia, a “safe, highly effective, and convenient” once-daily oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a broad spectrum parasiticide product for dogs. 

 

In November 2023, Elanco set a timeline for the (United States) (“U.S.”) approval of both Zenrelia and Credelio Quattro in the first half of 2024.

 

Then, in May 2024, Elanco set a timeline for the U.S. approval and commercial launch of Zenrelia in third quarter of 2024, as well as the U.S. approval of Credelio Quattro in the third quarter of 2024 with a commercial launch set for the fourth quarter of 2024.

 

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Zenrelia was less safe than the Company had led investors to believe; (ii) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro; (iii) accordingly, the Company’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

 

On June 27, 2024, the Company issued a press release providing an “innovation update” on Zenrelia and Credelio Quattro and their U.S. Food and Drug Administration (“FDA”) approval timelines.  The press release revealed that Elanco expected the U.S. label for Zenrelia to include a boxed warning on safety “based on the outcome of a trial with unvaccinated dogs dosed at 3x the label dose,” which the Company believed would “slow the product adoption curve in the U.S.” and initially limit the number of expected treatment days—i.e., the number of days Zenrelia can safely be administered to vaccinated dogs—by approximately 25%.  Further, Elanco stated that it was now expecting Zenrelia to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024, and that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024.

 

On this news, Elanco’s stock price fell $3.69 per share, or 20.53%, to close at $14.28 per share on June 27, 2024.

 

On an August 4, 2024 call held to discuss the Company’s Q2 2024 results, Elanco’s Chief Executive Officer Defendant Jeffrey N. Simmons (“Simmons”) provided further details on the Zenrelia boxed warning.  Specifically, Defendant Simmons stated that “this label language will slow the initial product adoption curve in the U.S. as we believe it will require focused veterinary education on the product” and “[o]ur expectations for treatment days being limited by approximately 25% is based on expected language in the box warning related to vaccine usage.”